{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Grade ≥ 3 Hematology"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade ≥ 3 Serum Chemistry"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry.\n\nGrade 3=severe Grade 4=life-threatening Grade 5=death","groups":[{"description":"Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W","id":"OG000","title":"Part A - Flat Dosing (AF)"},{"description":"Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W","id":"OG001","title":"Part A - Age/Weight-based Dosing (AW)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in part A","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days post last dose (Up to approximately 8 months)","title":"Number of Participants With Laboratory Abnormalities - Part A","type":"PRIMARY","unitOfMeasure":"Participants"}